There are influenza epidemics every year. Influenza B virus strains cause epidemics in humans as H1 and H3 subtype strains of influenza A virus. In contrast to the antigenicities of influenza A virus, those of influenza B virus are relatively stable (Lindstrom et al., 1999; McCullers et al., 1999) . Recent isolates of influenza B virus strains are divided into two large phylogenic trees: one group is represented by B/ Victoria/2/87 and the other is represented by B/Yamagata/ 16/88 (Kanegae et al., 1990) . B/Victoria group strains were dominant in the 1980s, while B/Yamagata strains became dominant in the early 1990s (Kanegae et al., 1990; Lindstrom et al., 1999; McCullers et al., 1999; Nerome et al., 1998; Rota et al., 1990; Yamashita et al., 1988) . Group-specific antigens have been conserved. Monoclonal antibody (mAb) 10B8 reacted with all B/Victoria group strains in haemagglutination inhibition (HI) and neutralization (NT) tests, while no reactivity was shown with B/Yamagata strains (Nakagawa et al., 1999) . The B/Victoria group neutralizing epitope is situated at the 'tip' of the haemagglutinin (HA) molecule. This observation is based on the phenomenon that amino acid residues of 10B8-induced escape mutants are either substituted or deleted in this region. B/Yamagata strains lack one to three amino acid residues in the tip; therefore, the epitope for 10B8 is specific for B/Victoria group strains. Furthermore, early B/Yamagata group strains, such as those isolated in 1984, have identities as high as 95 % with the B/Victoria group strains isolated at that time. This fact suggested that neutralizing antibodies, such as mAb 10B8, induced the B/Victoria group strains to create antigenic variants with amino acid deletions for survival and consequently, Yamagata group strains appeared (Nakagawa et al., 2001a) . In contrast to mAb 10B8, mAbs 5H4 and 3A12 reacted with all B/Yamagata strains in HI and NT tests. However, in Japan, 5H4-nonreacting strains appeared in the 1998-1999 season and have been increasing in number ever since. A single amino acid substitution at position 149 (ArgRLys) in the HA gene created these natural variants (Nakagawa et al., 2001b) .
antibody was provided by the National Institute of Infectious Diseases, Japan: the sera against B/Yamanashi/ 166/1998 for B/Yamagata strains. Human post-vaccination sera were collected at Baba Children's Clinic in Kadoma City, Osaka Prefecture, Japan. Results of HI and NT tests are expressed as the reciprocal of antibody dilution (Okuno et al., 1990) . Competitive assays were performed by modifying the method reported previously (Waxham & Wolinsky, 1985) . Escape mutants were induced by incubating B/Kadoma/122/1999 with mAb 3A12 by modifying the method described previously (Berton et al., 1984; Lambkin et al., 1994; Nakagawa et al., 2001a) . Briefly, 1610 5 f.f.u. ml 21 virus were incubated for 1 h at 30˚C in the presence of 10 ml mAb 3A12. The virus/mAb mixture was inoculated to Madin-Darby canine kidney cells in 24-well plates and incubated at 35˚C for 3 days. HI and NT tests on each well were performed separately with mAb in order to identify escape mutants. Nucleotide sequences of the escape mutants were analysed as described previously (Nakagawa et al., 2000 (Nakagawa et al., , 2001b . Briefly, RNA was obtained from the virus and influenza B virus-specific DNA was amplified by RT-PCR. Then the products were sequenced using the DYEnamic ET Terminator Cycle Sequencing kit (Amersham Pharmacia) and the ABI Prism 310 automatic sequencer (Perkin Elmer). As sequencing of the HA1 regions was carried out in two sections, two primer sets were prepared: 59-CTACTCATGGTAGTAACATCC-39 (nt 52-72) and 39-TGGGAAGCCACCAATCTGAGAAAC-59 (nt 774-751) for the first half and 59-ACCTCAGGATCTTGCCCTAACG-39 (positions 493-514) and 39-TGTGTATCCGTGCCAACCT-GCAAT-59 (positions 1194-1171) for the second half. mAb 3A12 was obtained by immunizing mice with a 5H4-nonreacting strain, as described above. Therefore, the epitopes of mAbs 3A12 and 5H4 should be distinct. However, in the competitive assay, excess amount of one mAb blocked almost 50 % of the binding of the other mAb to the virus (data not shown). To analyse the epitope sites precisely, further experiments with escape mutants were performed. We reported previously that two escape mutants (B/Kadoma/122/1999-V1 and -V2) were induced with mAb 5H4 and that they showed a single amino acid substitution at residue 149 (ArgRGly) or 141 (GlyRArg) of the HA1 protein, respectively (Nakagawa et al., 2001b) . In addition, nine mutants (B/Kadoma/122/1999-V3 to -V11) were induced with mAb 3A12 by incubating the same strain, B/Kadoma/122/1999. RLys) reacted well. The alternation of virus reactivity to polyclonal antibody depends greatly on which amino acid is substituted for the Arg residue at position 149. It is suggested that the structure of the HA protein is influenced more when Arg is substituted by a Gly residue rather than a Lys residue.
Amino acid sequences of the HA1 polypeptides of the influenza B virus strains were compared to those of A/Aichi/ 2/68 and numbered according to the A/Aichi sequence for ease of reference to the structure of the H3 HA molecule of influenza A virus (Berton et al., 1984; Krystal et al., 1982) . With this method, amino acid 141 is referred to as 137, 147
as 142, 148 as 143 and 149 as 144. Fig. 1 shows the threedimensional structure of the influenza A virus H3 HA molecule, as determined by Wilson et al. (1981) . Though the identified amino acid substitutions of influenza B virus are only predicted on the basis of sequence alignments, all of the amino acid residues above are suggested to be close to each other in the HA loop. The neutralizing epitopes of mAbs 5H4 and 3A12 are either overlapping or situated close enough to affect each other. The data of the competitive assay that the binding of one mAb was partially blocked by the other supported this idea. The loop, as well as the tip, has been reported as one of the most antigenic sites for the influenza virus HA protein. The variation in these regions is often observed in naturally occurring or laboratory-induced antigenic variants (Berton et al., 1984; Berton & Webster, 1985; Cleveland et al., 1997; Daniels et al., 1987; Lambkin et al., 1994; Luoh et al., 1992; Wiley et al., 1981) . In contrast to the B/Victoria group-specific epitope site being situated in the tip (Nakagawa et al., 2001a) , those of B/Yamagata strains are located in the loop. In addition, there exist more than two independent neutralizing sites in the loop. This is based on the fact that 5H4-nonreacting strains isolated from clinical specimens reacted well with mAb 3A12, as did three of the 3A12-escape mutants react with mAb 5H4 (Table 1) . Finally, it is of note that most 5H4-or 3A12-escape mutants failed to react well with polyclonal ferret antibody. Therefore, the loop plays an important role(s) in the neutralization of B/Yamagata group strains.
Group-specific antigens have been conserved for 10 years of B/Yamagata group strain epidemics. Actually, in Japan, the standard ferret sera were prepared using B/Mie/1/93 strain for the epidemic season in 1994 -1995 through 1998 . All 1998 B/Yamagata isolates in Osaka Prefecture reacted well with it in HI tests. However, the established human immunity began to induce naturally occurring antigenic variants (Fig. 2) . At first, in the 1998-1999 season, 5H4-nonreacting strains appeared with the amino acid substitution in the loop at residue 149 (ArgRLys) (Nakagawa et al., 2001b) . Then, in the 2000-2001 season, isolates were found to react only poorly to the polyclonal ferret antibody against the previous isolate. This phenomenon resulted from the amino acid substitution at residue 126 (AsnRAsp), which is situated outside of the loop (Nakagawa et al., 2002 When new amino acid substitutions or deletions take place in the loop, the virus gains distinct antigenicities from the existing ones and a new group of influenza B virus may appear from the variants. This information is of benefit to the management of public health; for example, for speculation on the scale of future epidemics and especially from the point of view of selecting suitable strains for vaccines.
